KRAS G12D T-cell receptors therapy (Earle A. Chiles Research Institute)

N/A

Report date: 2023/12/26 11:56:37

Base Information

Drug NameKRAS G12D T-cell receptors therapy (Earle A. Chiles Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEarle A. Chiles Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesEarle A. Chiles Research Institute
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A